A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

被引：0
|
作者：
Pin Zhang
Binghe Xu
Lin Gui
Wenna Wang
Meng Xiu
Xiao Zhang
Guilan Sun
Xiaoyu Zhu
Jianjun Zou
机构：
[1] National Cancer Center/Cancer Hospital,
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
[3] Jiangsu Hengrui Medicine Co. Ltd,undefined
来源：
Biomarker Research | / 9卷
关键词：
Cyclin-dependent kinase 4/6 inhibitor; Advanced breast cancer; First-in-human trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer
    Zhang, Pin
    Xu, Binghe
    Gui, Lin
    Wang, Wenna
    Xiu, Meng
    Zhang, Xiao
    Sun, Guilan
    Zhu, Xiaoyu
    Zou, Jianjun
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [2] A phase I study of SHR6390, a cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer (ABC).
    Zhang, Pin
    Xu, Binghe
    Gui, Lin
    Wang, Wenna
    Xiu, Meng
    Zhang, Xiao
    Sun, Guilan
    Zhu, Xiaoyu
    Zou, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients
    Tamura, Kenji
    Mukai, Hirofumi
    Naito, Yoichi
    Yonemori, Kan
    Kodaira, Makoto
    Tanabe, Yuko
    Yamamoto, Noboru
    Osera, Shozo
    Sasaki, Masaoki
    Mori, Yuko
    Hashigaki, Satoshi
    Nagasawa, Takashi
    Umeyama, Yoshiko
    Yoshino, Takayuki
    CANCER SCIENCE, 2016, 107 (06) : 755 - 763
  • [4] Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer
    Tamura, Kenji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (11) : 993 - 998
  • [5] Efficacy and safety of cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real-world experience
    Peng, Tzu-Rong
    Chen, Jia-Hui
    Wu, Ta-Wei
    THORACIC CANCER, 2023, 14 (30) : 3012 - 3019
  • [6] Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
    Micha, John P.
    Rettenmaier, Mark A.
    Bohart, Randy D.
    Goldstein, Bram H.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 547 - 551
  • [7] Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2-and HER2+advanced breast cancer
    Wang, Jingru
    Dong, Xiaotong
    Ashby, Charles R.
    Chen, Zhe-Sheng
    Zhang, Yunxiang
    DRUGS OF THE FUTURE, 2022, 47 (12) : 867 - 886
  • [8] A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced breast cancer
    Mita, Monica
    Joy, Anil A.
    Mita, Alain
    Sankhala, Kamalesh
    Moseley, Jennifer
    Zhang, Da
    Statkevich, Paul
    Jou, Ying-Ming
    Yao, Siu-Long
    Navarro, Mark
    Warren, Stephen L.
    Bannerji, Rajat
    Shapiro, Charles L.
    CANCER RESEARCH, 2011, 71
  • [9] The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification
    Shi, Chaoji
    Ju, Houyu
    Zhou, Rong
    Xu, Shengming
    Wu, Yunteng
    Gu, Ziyue
    Wang, Ying
    Chen, Wanling
    Huang, Xinyi
    Han, Yong
    Sun, Shuyang
    Li, Chuwen
    Wang, Min
    Zhou, Guoyu
    Zhang, Zhiyuan
    Li, Jiang
    Ren, Guoxin
    BMC MEDICINE, 2024, 22 (01):
  • [10] The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
    Tanaka, Tomohito
    Terai, Yoshito
    Ashihara, Keisuke
    Fujiwara, Satoe
    Tanaka, Yoshimichi
    Sasaki, Hiroshi
    Tsunetoh, Satoshi
    Ohmichi, Masahide
    PLOS ONE, 2017, 12 (05):
12345